Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial

BACKGROUND: Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer associated with poor survival outcomes in patients with distant metastatic disease (mMCC). In an initial analysis from JAVELIN Merkel 200, a phase 2, prospective, open-label, single-arm trial in mMCC, avelumab—a human anti–pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaufman, Howard L., Russell, Jeffery S., Hamid, Omid, Bhatia, Shailender, Terheyden, Patrick, D’Angelo, Sandra P., Shih, Kent C., Lebbé, Céleste, Milella, Michele, Brownell, Isaac, Lewis, Karl D., Lorch, Jochen H., von Heydebreck, Anja, Hennessy, Meliessa, Nghiem, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5774167/
https://www.ncbi.nlm.nih.gov/pubmed/29347993
http://dx.doi.org/10.1186/s40425-017-0310-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5774167/
https://www.ncbi.nlm.nih.gov/pubmed/29347993
http://dx.doi.org/10.1186/s40425-017-0310-x

Ejemplares similares